Variety of N-(4-phenyl-3-(2',3',4'(un) substituted phenyl)thiazol-2(3H)-ylidene)-2,4(un)substituted acridin-9-amine (4a-o) and 1-[(2,4-(un)substituted acridin-9-yl)-3-(4-phenyl-3-(2',3',4'(un)substituted phenyl)thiazol-2(3H)-ylidene)lisothiourea (5a-h) derivatives have been synthesized by condensation of 4-phenyl-3-(2',3',4'(un)substituted phenyl)thiazol-2(3H)-imine (3a-g) with 9-chloro-2,4-(un)substituted acridine (la-c) and 9-isothiocyanato-2,4-(un)substituted acridine (2a-d), respectively. All these compounds were characterized by correct H-1 NMR, FT-IR, MS and elemental analyses. These compounds were screened for antiinflammatory, analgesic and kinase (CDK1, CDK5 and GSK3) inhibition activities. Some compounds exhibited good anti-inflammatory (25-32%) and potent analgesic (50-75%) activities, at 50 mg/kg p.o. A compound, 4o (R-1 = H, R-2 = OCH3, R-3 = CH3, R-4 = CH3, R-5 = H) exhibited moderate CDK1 (IC50 = 8.5 mu M) inhibition activity. (c) 2005 Published by Elsevier Ltd.